Please assess the completion status of the following clinical trial:

Trial Title: DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women,~* Experiencing one symptom of vaginal atrophy (vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity or vaginal bleeding associated with sexual activity,~* Women having a low maturation index and a vaginal pH above 5,~* Endometrial thickness of 4 mm or less at transvaginal ultrasonography,~* Body weight within 18.5 and 32.0 according to body mass index.~Exclusion Criteria:~* Undiagnosed abnormal genital bleeding,~* Active or history of thromboembolic disease,~* Significant metabolic or endocrine disease,~* Significant complication on previous hormonal therapy,~* Use of hormonal implants within 6 months prior to study entry,~* Use of oral estrogen, progestin or DHEA in the 8 weeks prior to baseline,~* Use of natural (phytoestrogens) or herbal products in the 2 weeks prior to baseline,~* Chronic use of corticosteroids,~* Hypertension not controlled by standard therapy.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo suppository; once daily for 7 days.
- DHEA 0.50% (Type: EXPERIMENTAL): DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
- DHEA 1.0% (Type: EXPERIMENTAL): DHEA 1.0% (13 mg) suppository; once daily for 7 days.
- DHEA 1.8% (Type: EXPERIMENTAL): DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).